Nair Seixas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nair Seixas has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Ana Mendes Dias
Institute of Molecular Pathology and Immunology, University of Porto , Porto
1 shared publicationCláudia Sousa Rodrigues
Institute of Molecular Pathology and Immunology, University of Porto , Porto
1 shared publication- Inês Alves
Institute for Research and Innovation in Health (i3s), University of Porto, 4200-135 Porto, Portugal
1 shared publication Joana Gaifem
Institute of Molecular Pathology and Immunology, University of Porto , Porto
1 shared publication- José Oliveira
Research Center in Physical Activity, Health and Leisure (CIAFEL), Faculty of Sport, University of Porto, 4200-450 Porto, Portugal
1 shared publication Luis Malheiro
Departamento de Doenças Infeciosas, Centro Hospitalar Vila Nova de Gaia/Espinho , Gaia
1 shared publication
Latest Publications
- 15 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (6) , 1591-1598
SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis
COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. In this study, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor through the upregulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. This new evidence pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target. Key Points T cells from COVID-19 patients display less complex N-glycans at diagnosis. IL-2 is a putative driver of glycan switch in COVID-19 patients. DC-SIGN expression in monocytes at diagnosis predicts poor disease course.
- 15 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (6) , 1591-1598
SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis
COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. In this study, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor through the upregulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. This new evidence pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target. Key Points T cells from COVID-19 patients display less complex N-glycans at diagnosis. IL-2 is a putative driver of glycan switch in COVID-19 patients. DC-SIGN expression in monocytes at diagnosis predicts poor disease course.